---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-029010"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:54:55.876084+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xenon reports 2024 net loss $234.3M; CFO resigns; Phase 3 azetukalner FOS data due H2 2025

## Summary
- Net loss for 2024 was $234.3M ($65.7M Q4), vs $182.4M in 2023; R&D spend rose to $210.4M.
- Cash and marketable securities $754.4M as of Dec 31, 2024; sufficient to fund operations into 2027.
- Phase 3 X-TOLE2/3 azetukalner FOS topline data expected H2 2025; Phase 3 MDD and bipolar depression trials advancing.
- CFO Sherry Aulin resigns effective June 30, 2025, for personal reasons; will advise through Aug 31, 2025.
- Neurocrine collaboration milestone triggers $7.5M payment; Phase 1 study of Nav1.2/1.6 inhibitor initiated.

## SEC filing metadata
- accession: 0000950170-25-029010
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017025029010/0000950170-25-029010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017025029010/xene-20250224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-029010
- JSON: https://secwatch.observer/filing/0000950170-25-029010.json
- Plain text: https://secwatch.observer/filing/0000950170-25-029010.txt

## Key facts
- Executive change
  Sherry Aulin resigned as Chief Financial Officer at Xenon Pharmaceuticals Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On February 24, 2025, Ms. Sherry Aulin notified the Company of her decision to resign as Chief Financial Officer, effective June 30, 2025, for personal reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000095017025029010/0000950170-25-029010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.